Navigation Links
Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
Date:6/12/2008

rofile observed for belimumab suggest that it has the potential to play an important role in the treatment of SLE."

SLE is a chronic, life-threatening autoimmune disease. It is estimated that approximately 1.5 million people in the United States and approximately 5 million worldwide suffer from various forms of lupus, including SLE.

"At Week 52 in belimumab patients with serologically active SLE, we saw significant reductions in SLE disease activity versus placebo based on multiple measures of clinical effect, including the response rate chosen as the primary efficacy endpoint of the Phase 3 trials," said William W. Freimuth, M.D., Ph.D., Vice President, Clinical Research - Immunology, Rheumatology and Infectious Diseases. "We are encouraged by the continued improvement in these patients through three years. Belimumab could represent a significant advance in the treatment of SLE if Phase 2 results are confirmed in the Phase 3 trials that are currently ongoing."

LymphoStat-B (belimumab) is being developed by HGS and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in August 2006. The first Phase 3 data for LymphoStat-B are expected by mid- 2009, and all Phase 3 data to support regulatory filings are expected in fall 2009.

Key Findings from the Phase 2 Study Continuation Through Three Years

The data presented today at EULAR 2008 demonstrate that continued treatment with belimumab is associated with sustained improvement or stabilization of SLE disease activity in serologically active patients through three years of treatment. Belimumab decreased the frequency of SLE disease flares and reduced the need for high-dose steroids in these patients over time. The overall incidence of adverse events (in general and by system organ class), serious adverse events, infections, malignancies and laboratory abnormalities continued to decrease or stabilize from Week 52 to Week 160.

The evidence of sus
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
3. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
4. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
5. St. Jude Finds Dancing Hair Cells Are Key to Humans Acute Hearing
6. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
7. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
8. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
9. First Human Implant of New Archus Orthopedics Facet Replacement System
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... the Friday, December 19 edition of USA ... (HIT) features Konica Minolta, the company announced today. The supplement will ... healthcare organizations. In addition to the print section ... New York , Chicago , ... Minneapolis and San Francisco , ...
(Date:12/19/2014)... TODAY, AEGATE, the leader in medicine verification ... of Peter Fox as Chief Technology Officer ... Officer. Peter has served as Development Director ... Oracle in 2011. Prior to Datanomic, Peter ... and subsequently Convergys, a world renowned billing system for ...
(Date:12/19/2014)... 2014  Newport Corporation (NASDAQ: NEWP ... joined the company,s Board of Directors.  Dr. Kadia ... director of Evans Analytical Group, a leading global ... services to companies in a wide range of ... Analytical Group, Dr. Kadia spent nine years with ...
Breaking Medicine Technology:USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... term follow up results from chronically infected Hepatitis C,patients strongly confirm and exceed ... to show a statistically significant and long-term ... the way and strongly support move into a second generation, vaccine formulated ... ...
... the risk of,stroke by 34% in patient with atrial fibrillation ... adequately treated by ... of a,post-hoc analysis of the data from the ATHENA study ... European Society of Cardiology,congress 2008, in Munich, Germany. Previous results ...
Cached Medicine Technology:Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- The intestinal bacteria that ... ulcerative colitis, may be inherited, researchers report. The ... , could help in efforts to prevent the disease ... colitis, the study authors added. "The intestinal bacteria, ... age can have a big impact on your health ...
(Date:12/19/2014)... -- Potentially illness-causing E. coli bacteria were found on ... to a new study. Researchers checked cilantro, basil ... markets in Los Angeles and Orange counties in California, ... samples tested, 24 percent were positive for E. coli. ... researchers. Both types of bacteria can cause sometimes ...
(Date:12/19/2014)... Dec. 19, 2014 (HealthDay News) -- Dense bunches of bacteria ... cancers, a new study finds. The researchers said ... the colon. The presence of these biofilms may represent ... new way to predict a person,s risk for the disease, ... pond stones, these biofilms may coat the mucus layer of ...
(Date:12/19/2014)... News) -- Older adults who have lost all their teeth ... who still have at least some of their teeth, a ... loss could provide an early warning of increased risk of ... said. However, the findings don,t prove that tooth loss ... more than 3,100 participants 60 and older. People with no ...
(Date:12/19/2014)... December 19, 2014 Diet Doc strives ... current approach to weight loss by combining ... The professionals at the company understand that remaining committed ... effects of eliminating carbohydrates and sugars from the diet ... to abandon their weight loss goals. , For ...
Breaking Medicine News(10 mins):Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Could Bacteria Play a Role in Colon Cancer? 2Health News:Loss of Teeth Linked to Physical, Mental Decline in Study 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4
... Conference on Cell Therapy for Cardiovascular Disease sponsored ... comprehensive program dedicated to the evolving field of ... cardiac and vascular disease, as well as related ... conference will focus on preclinical and clinical studies ...
... The March of Dimes, along with its partners, are giving ... to learn from each other and to work together to ... give more babies a healthy start. U.S. Surgeon ... Prevention Symposium. The symposium will was a forum to share ...
... of researchers has discovered 13 new regions of the genome ... on the biological pathways involved in reproductive lifespan and will ... cancer and heart disease. Menopause is a ... in their early 50s. The timing of menopause can have ...
... Kathleen Doheny HealthDay Reporter , SUNDAY, Jan. ... genomic regions they believe are linked with breast cancer ... disease. All three newly identified areas "contain interesting ... clinical research," said researcher Douglas Easton, a professor of ...
... 2012) Research to Prevent Blindness (RPB) has awarded ... School, a $30,000 Medical Student Eye Research Fellowship. The award ... award will allow Ms. Shah to participate in research under ... Dr. Louis Pasquale in collaboration with Dr. Suzanne Freitag, Director ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, Jan. ... moratorium on controversial research into a modified avian flu virus ... Although the investigators believe their research has a public ... others that the genetically altered virus could escape from labs ...
Cached Medicine News:Health News:Global conference on stem cell therapy for heart disease to be held Jan. 25-27 in NYC 2Health News:Global conference on stem cell therapy for heart disease to be held Jan. 25-27 in NYC 3Health News:March of Dimes launches Prematurity Prevention Network 2Health News:March of Dimes launches Prematurity Prevention Network 3Health News:Genes and timing of menopause 2Health News:New Genetic Clues to Breast Cancer? 2Health News:New Genetic Clues to Breast Cancer? 3Health News:Scientists Agree to Delay Controversial Bird Flu Research 2Health News:Scientists Agree to Delay Controversial Bird Flu Research 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: